Our ongoing work indicates that CDK7 inhibition can enhance the transcriptional activity of TP53, as measured by TP53 regulated gene expression, and that this is particularly evident in HR+ breast cancer cell lines. This evidence concerns the gene CDK7 and breast carcinoma.